Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

Texas Oncology breaks ground on $120M cancer center in Plano

Texas Oncology on June 4 broke ground on a $120 million cancer center in Plano, marking a milestone for cancer care in North Texas.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Drugs & Targets

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

FDA approved the oral androgen receptor inhibitor Nubeqa (darolutamide) for the treatment of adult patients with metastatic castration-sensitive prostate cancer, which is also known as metastatic hormone-sensitive prostate cancer.

June 06, 2025

Vol.51 No.22

Drugs & Targets

EC approves Adcetris for newly diagnosed Hodgkin lymphoma in combination with ECADD

The European Commission June 3 approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone—a chemotherapy regimen—in adult patients with newly diagnosed stage 2b with risk factors, stage 3, and stage 4 Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use on April 25.

June 06, 2025

Vol.51 No.22

In Brief

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

On May 30, an international coalition announced the launch of CAR T Vision, a coalition that aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.

May 30, 2025

Vol.51 No.21

Clinical Roundup

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Mayo Clinic researchers have established the world’s first biobank of human salivary gland tissue-organoids to study chronic dry mouth, or xerostomia, an agonizing side effect of damaged salivary glands that affects millions.

May 23, 2025

Vol.51 No.20

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

YOU MAY BE INTERESTED IN

Texas Oncology breaks ground on $120M cancer center in Plano

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

FDA approves Nubeqa for metastatic castration-sensitive prostate cancer

EC approves Adcetris for newly diagnosed Hodgkin lymphoma in combination with ECADD

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Renew today!

Subscriber content

Never miss an issue!

Login